Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Corrigendum: Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection.

Bohannon C, Powers R, Satyabhama L, Cui A, Tipton C, Michaeli M, Skountzou I, Mittler RS, Kleinstein SH, Mehr R, Lee FE, Sanz I, Jacob J.

Nat Commun. 2016 Aug 16;7:12687. doi: 10.1038/ncomms12687. No abstract available.

2.

Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection.

Bohannon C, Powers R, Satyabhama L, Cui A, Tipton C, Michaeli M, Skountzou I, Mittler RS, Kleinstein SH, Mehr R, Lee FE, Sanz I, Jacob J.

Nat Commun. 2016 Jun 7;7:11826. doi: 10.1038/ncomms11826. Erratum in: Nat Commun. 2016 Aug 16;7:12687. Lee, Francis Eun-Hyung [Lee, Frances Eun-Hyung].

3.

Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans.

Quinn CP, Sabourin CL, Schiffer JM, Niemuth NA, Semenova VA, Li H, Rudge TL, Brys AM, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Parker SD, Babcock J, Keitel W, Poland GA, Keyserling HL, El Sahly H, Jacobson RM, Marano N, Plikaytis BD, Wright JG.

Clin Vaccine Immunol. 2016 Apr 4;23(4):326-38. doi: 10.1128/CVI.00696-15. Print 2016 Apr.

4.

Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice.

Lee S, Mittler RS, Moore ML.

J Immunol. 2014 Jan 1;192(1):293-9. doi: 10.4049/jimmunol.1300453. Epub 2013 Nov 27.

5.

Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice.

Kachapati K, Bednar KJ, Adams DE, Wu Y, Mittler RS, Jordan MB, Hinerman JM, Herr AB, Ridgway WM.

J Autoimmun. 2013 Dec;47:94-103. doi: 10.1016/j.jaut.2013.09.002. Epub 2013 Oct 18.

PMID:
24145149
6.

TLR2 signaling in tubular epithelial cells regulates NK cell recruitment in kidney ischemia-reperfusion injury.

Kim HJ, Lee JS, Kim A, Koo S, Cha HJ, Han JA, Do Y, Kim KM, Kwon BS, Mittler RS, Cho HR, Kwon B.

J Immunol. 2013 Sep 1;191(5):2657-64. doi: 10.4049/jimmunol.1300358. Epub 2013 Jul 31.

7.

The B10 Idd9.3 locus mediates accumulation of functionally superior CD137(+) regulatory T cells in the nonobese diabetic type 1 diabetes model.

Kachapati K, Adams DE, Wu Y, Steward CA, Rainbow DB, Wicker LS, Mittler RS, Ridgway WM.

J Immunol. 2012 Nov 15;189(10):5001-15. doi: 10.4049/jimmunol.1101013. Epub 2012 Oct 12.

8.

A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, Rudge TL, Mayfield HJ, Schiffer J, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Brys AM, Hunt RE, Levesque D, Estep JE, Barnewall RE, Robinson DM, Plikaytis BD, Marano N; AVRP Laboratory Working Group.

Clin Vaccine Immunol. 2012 Nov;19(11):1730-45. doi: 10.1128/CVI.00324-12. Epub 2012 Aug 29.

9.

Reverse signaling through the costimulatory ligand CD137L in epithelial cells is essential for natural killer cell-mediated acute tissue inflammation.

Kim HJ, Lee JS, Kim JD, Cha HJ, Kim A, Lee SK, Lee SC, Kwon BS, Mittler RS, Cho HR, Kwon B.

Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):E13-22. doi: 10.1073/pnas.1112256109. Epub 2011 Dec 12.

10.

Host CD25+CD4+Foxp3+ regulatory T cells primed by anti-CD137 mAbs inhibit graft-versus-host disease.

Kim J, Kim W, Kim HJ, Park S, Kim HA, Jung D, Choi HJ, Park SJ, Mittler RS, Cho HR, Kwon B.

Biol Blood Marrow Transplant. 2012 Jan;18(1):44-54. doi: 10.1016/j.bbmt.2011.09.004. Epub 2011 Sep 28.

11.

CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.

Qui HZ, Hagymasi AT, Bandyopadhyay S, St Rose MC, Ramanarasimhaiah R, Ménoret A, Mittler RS, Gordon SM, Reiner SL, Vella AT, Adler AJ.

J Immunol. 2011 Oct 1;187(7):3555-64. doi: 10.4049/jimmunol.1101244. Epub 2011 Aug 31.

12.

4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.

Vezys V, Penaloza-MacMaster P, Barber DL, Ha SJ, Konieczny B, Freeman GJ, Mittler RS, Ahmed R.

J Immunol. 2011 Aug 15;187(4):1634-42. doi: 10.4049/jimmunol.1100077. Epub 2011 Jul 8.

13.

Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus.

Skountzou I, Koutsonanos DG, Kim JH, Powers R, Satyabhama L, Masseoud F, Weldon WC, Martin Mdel P, Mittler RS, Compans R, Jacob J.

J Immunol. 2010 Aug 1;185(3):1642-9. doi: 10.4049/jimmunol.1000091. Epub 2010 Jun 28.

14.

Lineage-specific T-cell reconstitution following in vivo CD4+ and CD8+ lymphocyte depletion in nonhuman primates.

Engram JC, Cervasi B, Borghans JA, Klatt NR, Gordon SN, Chahroudi A, Else JG, Mittler RS, Sodora DL, de Boer RJ, Brenchley JM, Silvestri G, Paiardini M.

Blood. 2010 Aug 5;116(5):748-58. doi: 10.1182/blood-2010-01-263814. Epub 2010 May 18.

15.

Dendritic cells and Stat3 are essential for CD137-induced CD8 T cell activation-induced cell death.

Zhang B, Zhang Y, Niu L, Vella AT, Mittler RS.

J Immunol. 2010 May 1;184(9):4770-8. doi: 10.4049/jimmunol.0902713. Epub 2010 Mar 29.

16.

Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity.

Ganguly S, Liu J, Pillai VB, Mittler RS, Amara RR.

Vaccine. 2010 Feb 3;28(5):1300-9. doi: 10.1016/j.vaccine.2009.11.020. Epub 2009 Nov 26.

17.

A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, Bandura-Morgan L, Miller R, MacLeod KJ, Mittler RS, Shirwan H.

Vaccine. 2009 Dec 11;28(2):512-22. doi: 10.1016/j.vaccine.2009.09.127. Epub 2009 Oct 29.

18.

Hypercostimulation through 4-1BB distorts homeostasis of immune cells.

Lee SW, Salek-Ardakani S, Mittler RS, Croft M.

J Immunol. 2009 Jun 1;182(11):6753-62. doi: 10.4049/jimmunol.0803241.

19.

Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy.

Kim YH, Choi BK, Oh HS, Kang WJ, Mittler RS, Kwon BS.

Mol Cancer Ther. 2009 Feb;8(2):469-78. doi: 10.1158/1535-7163.MCT-08-0993. Epub 2009 Feb 3.

20.

Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation.

Bandyopadhyay S, Long M, Qui HZ, Hagymasi AT, Slaiby AM, Mihalyo MA, Aguila HL, Mittler RS, Vella AT, Adler AJ.

J Immunol. 2008 Dec 1;181(11):7728-37.

21.

Regulatory T cells participate in 4-1BB-mediated suppression of experimental allergic conjunctivitis.

Sumi T, Ishida W, Mittler RS, Yagita H, Taguchi O, Fukushima A.

Int Arch Allergy Immunol. 2009;148(4):305-10. doi: 10.1159/000170384. Epub 2008 Nov 11.

PMID:
19001790
22.

The IKK-neutralizing compound Bay11 kills supereffector CD8 T cells by altering caspase-dependent activation-induced cell death.

Lee SJ, Long M, Adler AJ, Mittler RS, Vella AT.

J Leukoc Biol. 2009 Jan;85(1):175-85. doi: 10.1189/jlb.0408248. Epub 2008 Oct 15.

23.

Bone marrow-based homeostatic proliferation of mature T cells in nonhuman primates: implications for AIDS pathogenesis.

Paiardini M, Cervasi B, Engram JC, Gordon SN, Klatt NR, Muthukumar A, Else J, Mittler RS, Staprans SI, Sodora DL, Silvestri G.

Blood. 2009 Jan 15;113(3):612-21. doi: 10.1182/blood-2008-06-159442. Epub 2008 Oct 1.

24.

Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells.

Lee SW, Park Y, So T, Kwon BS, Cheroutre H, Mittler RS, Croft M.

Nat Immunol. 2008 Aug;9(8):917-26. doi: 10.1038/ni.1632. Epub 2008 Jul 6.

25.

CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells.

Robertson SJ, Messer RJ, Carmody AB, Mittler RS, Burlak C, Hasenkrug KJ.

J Immunol. 2008 Apr 15;180(8):5267-74. Erratum in: J Immunol. 2008 Jul 15;181(2):1582.

26.

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.

McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, Sullenger B, Gilboa E.

J Clin Invest. 2008 Jan;118(1):376-86.

27.

Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent.

Zhang B, Maris CH, Foell J, Whitmire J, Niu L, Song J, Kwon BS, Vella AT, Ahmed R, Jacob J, Mittler RS.

J Clin Invest. 2007 Oct;117(10):3029-41.

28.

CD137 ligand prevents the development of T-helper type 2 cell-mediated allergic asthma by interferon-gamma-producing CD8+ T cells.

Polte T, Jagemann A, Foell J, Mittler RS, Hansen G.

Clin Exp Allergy. 2007 Sep;37(9):1374-85.

PMID:
17845419
29.

CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.

Lee SJ, Rossi RJ, Lee SK, Croft M, Kwon BS, Mittler RS, Vella AT.

J Immunol. 2007 Aug 15;179(4):2203-14.

30.

Distinct approaches to investigate the importance of the murine 4-1BB 4-1BBL interaction in the antibody response to Streptococcus pneumoniae.

Moens L, Jeurissen A, Mittler RS, Wuyts G, Michiels G, Boon L, Ceuppens JL, Bossuyt X.

J Leukoc Biol. 2007 Sep;82(3):638-44. Epub 2007 Jun 5.

PMID:
17550973
31.

Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, Spencer T, Dillehay D, Kwon B, Chen L, Vella AT, Mittler RS.

J Immunol. 2007 Apr 1;178(7):4194-213.

32.

T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity.

Foell J, Hewes B, Mittler RS.

Curr Cancer Drug Targets. 2007 Feb;7(1):55-70. Review.

PMID:
17305478
33.

Antigen-specific CD4+ T cells recognize epitopes of protective antigen following vaccination with an anthrax vaccine.

Laughlin EM, Miller JD, James E, Fillos D, Ibegbu CC, Mittler RS, Akondy R, Kwok W, Ahmed R, Nepom G.

Infect Immun. 2007 Apr;75(4):1852-60. Epub 2007 Feb 5. Erratum in: Infect Immun. 2007 Sep;75(9):4670.

34.

Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes.

Irie J, Wu Y, Kachapati K, Mittler RS, Ridgway WM.

Diabetes. 2007 Jan;56(1):186-96.

35.

TGFbeta protein processing and activity through TCR triggering of primary CD8+ T regulatory cells.

Ménoret A, Myers LM, Lee SJ, Mittler RS, Rossi RJ, Vella AT.

J Immunol. 2006 Nov 1;177(9):6091-7.

36.

Costimulatory molecules as immunotherapeutic targets in systemic lupus erythematosus.

Foell J, Mittler RS.

Springer Semin Immunopathol. 2006 Oct;28(2):153-62. Epub 2006 Sep 2. Review.

PMID:
16951932
37.

Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy.

McMillin DW, Hewes B, Gangadharan B, Archer DR, Mittler RS, Spencer HT.

Hum Gene Ther. 2006 Aug;17(8):798-806.

PMID:
16942440
38.

Eradication of established tumors in mice by a combination antibody-based therapy.

Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, Gejyo F, Okumura K, Yagita H, Smyth MJ.

Nat Med. 2006 Jun;12(6):693-8. Epub 2006 May 7.

PMID:
16680149
39.

CD137-mediated immunotherapy for allergic asthma.

Polte T, Foell J, Werner C, Hoymann HG, Braun A, Burdach S, Mittler RS, Hansen G.

J Clin Invest. 2006 Apr;116(4):1025-36. Epub 2006 Mar 9.

40.

Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells.

Myers L, Lee SW, Rossi RJ, Lefrancois L, Kwon BS, Mittler RS, Croft M, Vella AT.

Int Immunol. 2006 Feb;18(2):325-33. Epub 2005 Dec 22.

PMID:
16373363
41.

Engagement of 4-1BB inhibits the development of experimental allergic conjunctivitis in mice.

Fukushima A, Yamaguchi T, Ishida W, Fukata K, Mittler RS, Yagita H, Ueno H.

J Immunol. 2005 Oct 15;175(8):4897-903.

42.

Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor.

Nishimoto H, Lee SW, Hong H, Potter KG, Maeda-Yamamoto M, Kinoshita T, Kawakami Y, Mittler RS, Kwon BS, Ware CF, Croft M, Kawakami T.

Blood. 2005 Dec 15;106(13):4241-8. Epub 2005 Aug 25.

43.

Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression.

Myers L, Croft M, Kwon BS, Mittler RS, Vella AT.

J Immunol. 2005 Jun 15;174(12):7625-32.

44.
45.

Suppressing the self in rheumatoid arthritis.

Mittler RS.

Nat Med. 2004 Oct;10(10):1047-9. No abstract available.

PMID:
15459704
46.

Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.

Cho HR, Kwon B, Yagita H, La S, Lee EA, Kim JE, Akiba H, Kim J, Suh JH, Vinay DS, Ju SA, Kim BS, Mittler RS, Okumura K, Kwon BS.

Transpl Int. 2004 Aug;17(7):351-61. Epub 2004 Jul 31.

47.

4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function.

Lee SJ, Myers L, Muralimohan G, Dai J, Qiao Y, Li Z, Mittler RS, Vella AT.

J Immunol. 2004 Sep 1;173(5):3002-12.

48.

Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance.

Foell JL, Diez-Mendiondo BI, Diez OH, Holzer U, Ruck P, Bapat AS, Hoffmann MK, Mittler RS, Dannecker GE.

Immunology. 2004 Sep;113(1):89-98.

49.

4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.

Munks MW, Mourich DV, Mittler RS, Weinberg AD, Hill AB.

Immunology. 2004 Aug;112(4):559-66.

50.

Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.

Mittler RS, Foell J, McCausland M, Strahotin S, Niu L, Bapat A, Hewes LB.

Immunol Res. 2004;29(1-3):197-208. Review.

PMID:
15181282

Supplemental Content

Loading ...
Support Center